Market news

TG Therapeutics (NASDAQ:TGTX) Chairman, President and Chief Executive Officer Mike Weiss said the company’s multiple sclerosis therapy, BRIUMVI, has captured more than one-third of the intravenous anti-CD20 market and continues to gain share as it approaches its fourth full year on the market. Spea

TG Therapeutics (TGTX) steps into the spotlight ahead of its H.C. Wainwright conference appearance on September 14, drawing fresh attention after the stock recently bounced off its 50-day moving average. Across the past few months, TG Therapeutics has leaned into stronger momentum, with a 30-day share price return of 12.36% and a year-to-date share price return of 92.86%. The one-year total shareholder return of 73.17% and roughly 5x three-year total shareholder return suggest earlier buyers...

TG Therapeutics stock showed technical strength Wednesday, bounding off its 50-day moving average and nearing a breakout on the weekly chart.

Fireside chat scheduled for Wednesday, September 9, 2026, at 11:30am ETNEW YORK, Sept. 03, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, will participate in the Cantor Global Healthcare Conference, being held on September 9 - 11, 2026. The fireside chat is scheduled to take place on Wednesday, September 9, 2026, at 11:30am ET. A live webcast of the fireside chat will be available on the Eve

Detailed price information for Tg Therapeutics (TGTX-Q) from The Globe and Mail including charting and trades.

The multiple sclerosis biotech has topped an early entry and is near a breakout.

TGTX stock is recovering from an earnings sell-off in early August. building a base. The biotech stock is testing a key moving average.

TG Therapeutics stock rips higher on takeover speculation. But should you chase the momentum on Friday? Let’s find out!

908 Devices outlined its strategy to focus exclusively on handheld chemical and drug detection technologies for public safety and defense markets, following the divestiture of its life-sciences business line about 15 months ago. Speaking at a Canaccord Genuity event, President, CEO and Co-Founder K

Detailed price information for Tg Therapeutics (TGTX-Q) from The Globe and Mail including charting and trades.

Detailed price information for Tg Therapeutics (TGTX-Q) from The Globe and Mail including charting and trades.

TG Therapeutics (TGTX) drew fresh attention after reporting second quarter 2026 results, with revenue of US$240.34 million and earnings of US$0.05 per share, alongside higher full-year revenue guidance near US$950 million. See our latest analysis for TG Therapeutics. Despite raising guidance and reporting strong revenue growth for BRIUMVI, TG Therapeutics has seen its recent momentum cool, with the share price down 11.26% over 1 day and 15.86% over 7 days. However, the year-to-date share...

Moby summary of TG Therapeutics, Inc.'s Q2 2026 earnings call

Top-notch biotech stocks TG Therapeutics and Twist Bioscience diverged Monday on mixed earnings reports.

The headline numbers for TG Therapeutics (TGTX) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

TG Therapeutics, Inc. (NASDAQ:TGTX) increased its full-year 2026 revenue guidance after reporting another quarter of strong sales growth for its multiple sclerosis treatment, Briumvi, according to the company’s latest earnings release.

TG Therapeutics (TGTX) delivered earnings and revenue surprises of -87.81% and +4.08%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

TG Therapeutics, Inc. (TGTX) reported Q2 earnings Monday of $0.05 per diluted share, down from $0.17

TG Therapeutics: Q2 Earnings Snapshot

Second quarter 2026 total global revenue of approximately $240 million, including BRIUMVI U.S. net product revenue of approximately $228 million Raises full year 2026 total global revenue target to approximately $950 million and raises full year 2026 BRIUMVI U.S. net product revenue target to approximately $890 - 905 million Conference call to be held today, Monday, August 3, 2026, at 8:30 AM ET NEW YORK, Aug. 03, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) (the Company or TG T

TG Therapeutics (NASDAQ:TGTX) reported second-quarter 2026 revenue of $240 million and raised its full-year sales outlook for BRIUMVI, its treatment for relapsing multiple sclerosis, as the company cited record new patient starts, continued prescriber expansion and higher-than-expected treatment per

The biotech firm increased its 2026 total global revenue target to around $950 million, up from $925 million previously.

Conference Call to be Held Monday, August 3, 2026, at 8:30 am ETNEW YORK, July 29, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held, Monday, August 3, 2026, at 8:30 AM ET to discuss results for the second quarter 2026 and to provide a business outlook for the remainder of 2026. Michael S. Weiss, Chairman and Chief Executive Officer, will host the call. In order to participate in the conference call, please call 1-877-407-8029 (U.S

TG Therapeutics (TGTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Detailed price information for Tg Therapeutics (TGTX-Q) from The Globe and Mail including charting and trades.

Detailed price information for Protagonist Therapeutics Inc (PTGX-Q) from The Globe and Mail including charting and trades.

ClearBridge Investments, a global equity manager, recently published second-quarter 2026 commentary for its “SMID Cap Growth Strategy”. A copy can be downloaded here. Small and mid-cap (SMID) growth equities experienced the strongest quarter in recent memory, with the Russell 2500 Growth Index rising 24.0%, driven by enthusiasm for AI infrastructure and higher-beta momentum stocks. The […]

TG Therapeutics stock has delivered a 124.8% return over the past three years, and the valuation checks now suggest the shares still lean towards the cheaper side rather than looking fully priced. A 124.8% return over three years points to a stock that has already rewarded investors, so the key issue is whether that past gain has already captured most of the easy upside. The expansion of BRIUMVI into new indications such as treatment resistant schizophrenia can support higher long term...

TG Therapeutics, Inc. (NASDAQ:TGTX) is one of the 10 Best Performing American Stocks in June 2026. On July 6, 2026, TG Therapeutics, Inc. (NASDAQ:TGTX) announced the initiation of a Phase 2 clinical trial evaluating Briumvi in adults with treatment-resistant schizophrenia. The open-label study is designed to evaluate the efficacy and safety of Briumvi in approximately […]

TG Therapeutics recently initiated an open-label Phase 2 trial of BRIUMVI (ublituximab-xiiy) in about 60 adults with treatment-resistant schizophrenia who will remain on standard antipsychotic therapy, measuring response by a 20% or greater reduction in PANSS total score at Week 12. This move tests whether B-cell depletion, already used in multiple sclerosis, could address a difficult-to-treat subset of schizophrenia and meaningfully broaden BRIUMVI’s clinical footprint. We’ll now explore...

TG Therapeutics (TGTX) has attracted fresh attention after announcing a Phase 2 clinical trial of BRIUMVI in adults with treatment-resistant schizophrenia, a small open-label study conducted alongside standard antipsychotic therapy. See our latest analysis for TG Therapeutics. TG Therapeutics has seen strong momentum around this news, with the share price at US$58.06 and a 30-day share price return of 44.57% alongside a 1-year total shareholder return of 63.04%. This points to sentiment that...

TGTX initiates a phase II study evaluating Briumvi in adult patients with treatment-resistant schizophrenia. Shares rise.

Phase 2 trial to evaluate the effects of B-cell depletion with BRIUMVI in approximately 60 patients with treatment-resistant schizophrenia based on emerging evidence linking immune dysfunction to disease in a subset of patientsNEW YORK, July 06, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced the initiation of a Phase 2 clinical trial evaluating BRIUMVI® (ublituximab-xiiy), in adults with treatment-resistant schizophrenia. The Phase 2 study is an open-label trial de